Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416033
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
Serum Irisin Level In Leprosy Patients
Sponsor:
Aswan University
Organization:
Aswan University
Study Overview
Official Title:
Serum Irisin Level In Leprosy Patients
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Measurement of plasma irisin level in leprosy patients
Correlation of plasma irisin level between leprosy patients and healthy controls
Correlation of plasma irisin level in different leprosy types
Correlation of plasma irisin level between leprosy patients and healthy controls
Correlation of plasma irisin level in different leprosy types
Detailed Description:
Leprosy is a chronic granulomatous infectious disease which infects mainly superficial peripheral nerves mucosa of upper respiratory tract testicles bones and eyes Its an intracellular infection caused by the acid-fast bacillus Mycobacterium leprae
Both age and sex are important risk factors for leprosy infection adolescents aged between 10 and 19 years and adults aged more than 30 years are more liable to leprosy and the possibility of leprosy infection of adult males is twice as much as adult females
Leprosy evolution involves complex host immune mechanisms that influence the clinical presentation of the disease the spectral pathology of leprosy can be diagnosed by using two coexisting classification systems The WHO classification system which is based on the number of lesions and Ridley and Jopling classification system which is based on the histopathology
The WHO classification system includes individuals with more than five lesions which are classified as multibacillary MB patients and individuals with less than five lesions which are classified as paucibacillary PB patients While Ridley and Jopling classification system includes tuberculoid leprosy TT lepromatous leprosy LL and borderline phenotypes borderline tuberculoid BT mid-borderline BB and borderline lepromatous BL
Tuberculoid leprosy TT is characterized by the presence of one to three cutaneous lesions called plaques These lesions are circular or oval erythematoushypopigmented hairless scaly dry and anesthetic On the other hand lepromatous leprosy LL is characterized by extensive and multiple bilateral lesions which may include macules papules nodules and plaques
The majority of patients however present with the borderline phenotypes In these phenotypes the bacterial load correlates with the histological features borderline tuberculoid BT being more closely related to tuberculoid leprosy TT patients while borderline lepromatous BL to lepromatous leprosy LL patients The borderline states are immunologically unstable and susceptible to the occurrence of leprosy reactions
In 1991 the World Health Assembly decided to eliminate leprosy as a public health problem by the year 2000 Elimination was defined as decreasing the disease prevalence globally to less than 1 case per 10000 populations In 2000 the World Health Organization WHO announced that elimination was reached globally
Irisin is a protein formed of 112 amino acids It was discovered in 2012 at Harvard University And named after an ancient Goddess called Iris who served as a messenger among the Gods in Greek mythology
Irisin has been linked to many metabolic diseases including obesity lipid metabolism cardiovascular disease CVD type 2 diabetes mellitus T2DM polycystic ovary syndrome PCOS Nonalcoholic fatty liver disease NAFLD and metabolic bone diseases
Both age and sex are important risk factors for leprosy infection adolescents aged between 10 and 19 years and adults aged more than 30 years are more liable to leprosy and the possibility of leprosy infection of adult males is twice as much as adult females
Leprosy evolution involves complex host immune mechanisms that influence the clinical presentation of the disease the spectral pathology of leprosy can be diagnosed by using two coexisting classification systems The WHO classification system which is based on the number of lesions and Ridley and Jopling classification system which is based on the histopathology
The WHO classification system includes individuals with more than five lesions which are classified as multibacillary MB patients and individuals with less than five lesions which are classified as paucibacillary PB patients While Ridley and Jopling classification system includes tuberculoid leprosy TT lepromatous leprosy LL and borderline phenotypes borderline tuberculoid BT mid-borderline BB and borderline lepromatous BL
Tuberculoid leprosy TT is characterized by the presence of one to three cutaneous lesions called plaques These lesions are circular or oval erythematoushypopigmented hairless scaly dry and anesthetic On the other hand lepromatous leprosy LL is characterized by extensive and multiple bilateral lesions which may include macules papules nodules and plaques
The majority of patients however present with the borderline phenotypes In these phenotypes the bacterial load correlates with the histological features borderline tuberculoid BT being more closely related to tuberculoid leprosy TT patients while borderline lepromatous BL to lepromatous leprosy LL patients The borderline states are immunologically unstable and susceptible to the occurrence of leprosy reactions
In 1991 the World Health Assembly decided to eliminate leprosy as a public health problem by the year 2000 Elimination was defined as decreasing the disease prevalence globally to less than 1 case per 10000 populations In 2000 the World Health Organization WHO announced that elimination was reached globally
Irisin is a protein formed of 112 amino acids It was discovered in 2012 at Harvard University And named after an ancient Goddess called Iris who served as a messenger among the Gods in Greek mythology
Irisin has been linked to many metabolic diseases including obesity lipid metabolism cardiovascular disease CVD type 2 diabetes mellitus T2DM polycystic ovary syndrome PCOS Nonalcoholic fatty liver disease NAFLD and metabolic bone diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None